IOVAIovance Biotherapeutics, Inc.

$2B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$86M

Net Income

-$86M

EPS (Diluted)

$-0.55

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$58M

Free Cash Flow

-$67M

Stock-Based Comp.

$19M

Balance Sheet

Total Assets

$829M

Total Liabilities

$130M

Stockholders' Equity

$698M

Cash & Equivalents

$59M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$86M	-$59M	-46.3%
Net Income	-$86M	-$59M	-47.0%

IOVA Q3 2021 Earnings — Iovance Biotherapeutics, Inc. Revenue & Financial Results | Market Cap Arena